Dyslipidemie

PCSK9 inhibitor treatment and outcomes

Why choose PRALUENT®?

Prevent the Event

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.¹

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262